Vise Technologies Inc. Purchases New Position in Amgen Inc. $AMGN

Vise Technologies Inc. acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, HoldingsChannel reports. The fund acquired 38,406 shares of the medical research company’s stock, valued at approximately $16,189,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AMGN. Wellington Altus USA Inc. raised its stake in Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after buying an additional 34 shares in the last quarter. Nvwm LLC lifted its holdings in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after buying an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen during the 2nd quarter valued at $36,000. PFS Partners LLC boosted its position in Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 42 shares in the last quarter. Finally, Evergreen Advisors LLC purchased a new position in shares of Amgen in the 1st quarter valued at $37,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Mizuho raised their price objective on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Morgan Stanley cut their target price on Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 7th. Piper Sandler lifted their target price on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Finally, HSBC downgraded shares of Amgen from a “buy” rating to a “hold” rating and reduced their target price for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $389.71.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Performance

Shares of AMGN stock opened at $466.01 on Monday. The business’s fifty day simple moving average is $419.96 and its 200-day simple moving average is $374.79. The company has a market cap of $251.94 billion, a PE ratio of 28.96, a PEG ratio of 3.41 and a beta of 0.43. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $475.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts expect that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is currently 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.